Harrow, Inc. Stock Issued During Period, Value, Employee Benefit Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Harrow, Inc. stock issued during period, value, employee benefit plan for the quarter ending 2024-12-31 was $105.00K, a 337.50% increase year-over-year.
- Harrow, Inc. stock issued during period, value, employee benefit plan for the quarter ending 2024-09-30 was $484.00K, a 2588.89% increase year-over-year.
- Harrow, Inc. stock issued during period, value, employee benefit plan for the quarter ending 2024-06-30 was $173.00K, a 66.35% increase year-over-year.
- Harrow, Inc. stock issued during period, value, employee benefit plan for the quarter ending 2024-03-31 was $348.00K, a 135.14% increase year-over-year.
- Harrow, Inc. stock issued during period, value, employee benefit plan for fiscal 2025 was $467.00K, a 57.93% decline from fiscal 2024.
- Harrow, Inc. stock issued during period, value, employee benefit plan for fiscal 2024 was $1.11M, a 277.55% increase from fiscal 2023.
- Harrow, Inc. stock issued during period, value, employee benefit plan for fiscal 2023 was $294.00K, a 49.91% decline from fiscal 2022.
- Harrow, Inc. stock issued during period, value, employee benefit plan for fiscal 2022 was $587.00K, a 803.08% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Benefit Plan 3 month | Stock Issued During Period, Value, Employee Benefit Plan 12 month |
|---|---|---|
| 2025-12-31 | $467.00K 10-K · filed 2026-03-02 | |
| 2024-12-31 | $105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.11M 10-K · filed 2026-03-02 |
| 2024-09-30 | $484.00K 10-Q · filed 2024-11-14 | $1.03M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $173.00K 10-Q · filed 2024-08-07 | $563.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $348.00K 10-Q · filed 2024-05-13 | $494.00K derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $294.00K 10-K · filed 2026-03-02 |
| 2023-09-30 | $18.00K 10-Q · filed 2024-11-14 | $850.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $104.00K 10-Q · filed 2024-08-07 | $832.00K derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $148.00K 10-Q · filed 2024-05-13 | $731.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $580.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $587.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $7.00K derived: sum of 4 quarters · filed 2023-03-23 |
| 2022-06-30 | $3.00K 10-Q · filed 2022-08-09 | $24.00K derived: sum of 4 quarters · filed 2023-03-23 |
| 2022-03-31 | $4.00K 10-Q · filed 2022-05-05 | $42.00K derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $65.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $17.00K 10-Q · filed 2022-11-14 | $86.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $21.00K 10-Q · filed 2022-08-09 | $77.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $27.00K 10-Q · filed 2022-05-05 | |
| 2020-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $29.00K 10-K · filed 2021-03-08 |
| 2020-09-30 | $8.00K 10-Q · filed 2020-11-09 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $44.00K 10-K · filed 2021-03-08 |
| 2019-09-30 | $44.00K 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $75.00K 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $150.00K 10-K · filed 2019-03-12 | |
| 2018-03-31 | $108.00K 10-Q · filed 2019-05-09 | |
| 2017-12-31 | $60.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |